Doris Benbrook to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Doris Benbrook has written about Xenograft Model Antitumor Assays.
Connection Strength
0.506
-
Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int J Cancer. 2020 08 15; 147(4):1086-1097.
Score: 0.160
-
Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther. 2009 May; 8(5):1227-38.
Score: 0.076
-
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs. 2009 Aug; 27(4):304-18.
Score: 0.073
-
Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs. 2005 Oct; 23(5):417-28.
Score: 0.060
-
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol. 2021 01; 160(1):302-311.
Score: 0.042
-
Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS J. 2020 02 21; 22(2):51.
Score: 0.040
-
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
Score: 0.035
-
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008 Jul 01; 68(13):5335-44.
Score: 0.018